4immune Therapeutics

4immune’s lead program targets patients with early-stage type 1 diabetes (T1D), a T cell-mediated autoimmune disorder in which a person’s own immune cells destroy the insulin-producing beta cells in the pancreas. Our pipeline includes our lead therapeutic for early-stage type 1 diabetes, as well as ongoing discovery of treatments targeting multiple sclerosis and rheumatoid arthritis. From company website Source · Oct 13, 2026

Keywords: immunology metabolic autoimmune diseases cell therapy